Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
NCT04793399 · Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica · PHASE1/PHASE2 · terminated · last registry update 2024-03-19 · Chronic myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.” | Open Targets' class: safety sideeffects | Registry record, Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in chronic myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-10Results posted on the registry: Novartis Pharmaceuticals, Imatinib + Nilotinib (NCT04971226)
- 2025-02-14Results posted on the registry: Novartis Pharmaceuticals, Asciminib add-on + Imatinib (NCT03578367)
- 2025-01-17Also stopped (terminated): Gruppo Italiano Malattie EMatologiche dell'Adulto, Ponatinib (NCT02398825)
- 2024-07-12Results posted on the registry: Novartis Pharmaceuticals, ABL001 (NCT04666259)
- 2024-05-21Phase 3 first posted: Ascentage Pharma Group Inc., olverembatinib + Bosutinib (NCT06423911)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision